Seventh Sense Biosystems, Inc., a Cambridge, MA-based blood sampling and health diagnostics company, has raised $4.5m of a two-tranche $10m extension of its Series A financing.
Investors include existing backers Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.
The company intends to use the new funds to advance development of its proprietary Touch Activated Phlebotomy™ (TAP) technology platform, which is designed to enable one-step blood collection in a safe, painless and convenient manner.
The TAP system penetrates the uppermost layers of skin and uses a proprietary microfluidic extraction process to transfer blood to a collection reservoir for analysis. TAP’s design can be integrated into a broad range of products across a wide spectrum of diagnostic applications.
Founded in 2008, Seventh Sense Biosystems is led by President and Chief Executive Officer Doug Levinson, Ph.D.